• Expert Rev Anticancer Ther · Mar 2007

    Review

    Rituximab and its role as maintenance therapy in non-Hodgkin lymphoma.

    • Bridgette Collins-Burow and Edgardo S Santos.
    • Tulane University School of Medicine, Division of Hematology-Medical Oncology, Tulane Cancer Center, 1430 Tulane Avenue, SL-78, New Orleans, LA 70112, USA. bcollin1@tulane.edu
    • Expert Rev Anticancer Ther. 2007 Mar 1; 7 (3): 257-73.

    AbstractSince rituximab, a chimeric monoclonal anti-CD20 antibody, was introduced into clinical practice in 1997, data regarding its benefit in terms of response rate, quality of response, progression-free survival and overall survival in B-cell lymphoid malignancies continues to expand. Rituximab has proven to be a relatively well-tolerated drug, with its major side effects being infusion related. Rituximab was approved initially by the US FDA and the European Medicines Agency for relapsed or refractory low-grade or follicular CD20+ B-cell non-Hodgkin lymphomas. Subsequently, its use has been extended to include first-line therapy in low-grade lymphoma as well as the treatment of more aggressive histological subtypes such as diffuse large B-cell lymphoma. In this article, we review the landmark trials that have impacted clinical practice in follicular and diffuse large B-cell lymphomas and the emerging data for use of rituximab as maintenance therapy in non-Hodgkin lymphoma.

      Pubmed     Full text   Copy Citation     Plaintext  

      Add institutional full text...

    Notes

     
    Knowledge, pearl, summary or comment to share?
    300 characters remaining
    help        

    hide…

Want more great medical articles?

Keep up to date with a free trial of metajournal, personalized for your practice.
1,694,794 articles already indexed!

We guarantee your privacy. Your email address will not be shared.